If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
ARYA Sciences Acquisition III (ARYA)
Upcoming IPO
Vistas Media Acquisition (VMACU)
Hitek Global (HKIT)
Presidio Property Trust (SQFT)
PainReform (PRFX)
PaxMedica (PXMD)
Duck Creek Technologies, Inc. (DCT)
Priced IPO
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
Rackspace Technology, Inc. (RXT)
BigCommerce Holdings, Inc (BIGC)
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
More companies

Inari Medical, Inc. (NARI)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Their initial product offering consists of two minimally-invasive, novel catheter-based mechanical thrombectomy devices. They purpose-built their products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE -- deep vein thrombosis and pulmonary embolism. Their ClotTriever product is FDA-cleared for the removal of clot from peripheral blood vessels and is used to treat patients suffering from deep vein thrombosis, or DVT. Their FlowTriever product is the first thrombectomy system FDA-cleared for the treatment of pulmonary embolism, or PE. These products have been used to treat more than 6,700 patients at approximately 500 hospitals across the United States, with approximately 90% of cases being performed since they launched their broader commercial efforts in the third quarter of 2018. They have experienced significant growth since they began commercializing their products and have had strong momentum in their business in 2019, with 4,562 procedures performed using their products in 2019.
William Hoffman Mitchell Hill
Employees Founded
240 2011


Address: 9 Parker, Suite 100, Irvine, CA 92618, US

Telephone: (877) 923-4747

Web page:

IPO information

Expected Date 5/22/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range $14.00-$16.00
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $806.4
Revenues (MM) $71.1
Net Income (Loss) (MM) $3.9


What do you think will happen with the NARI share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 7.33
Shares Revised (MM) 8.2
Expected offer amount (MM) $109.95
Realized offer amount(MM) $155.8
BofA Securities/ Morgan Stanley
Canaccord Genuity/ Wells Fargo Securities

Sector: Healthcare

Tweets about $NARI

Tweets volume:

RT volume:


Google Trends Stats